VSV-02

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameVSV-02
Drug Alias NameVSV-02
ClassificationBiologics > Oncolytic virusVaccines > Application > Therapeutic vaccineBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4] 
Mechanisms of ActionAnti-CD3Anti-Programmed death-ligand 1
TargetsT cell surface glycoprotein CD3Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursLung NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJoint Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xinxiang Medical University
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A